Astellas Pharma Inc. FY2027 Q1 Earnings Report

Quick View

Executive Summary

Astellas Pharma’s 2026 fiscal year Q1 results showed higher revenue and profits, along with a significant improvement in margins, driven by rapid growth in key strategic products and the lapping of temporary cost factors. Revenue was ¥640.91B (+26.7% year on year), Operating Income was ¥184.51B (+94.9%), and quarterly Net Income attributable to owners of the parent was ¥141.83B (+107.3%). The Operating Income margin improved by 10.1pt to 28.8%, from 18.7% in the same period of the previous year; however, it should be noted that this improvement also includes the temporary effect of lapping the ¥13.55B impairment loss recorded in the same period of the previous year. Top-line growth was led by combined growth of +43% in key strategic products such as PADCEV, IZERVAY, and VYLOY, as disclosed by the Company, as well as +19% growth in the core product XTANDI.

Factors Driving Performance Changes

【Revenue】Revenue increased 26.7% year on year to ¥640.91B. According to Company disclosures, the combined sales of key strategic products—PADCEV, IZERVAY, VYLOY, VEOZAH, and XOSPATA—increased sharply by +43% year on year and was the primary driver of revenue growth. XTANDI, the product with the largest revenue mix, also grew +19% and contributed to the increase in revenue. The Company disclosed a positive foreign-exchange impact of ¥60B on revenue, and yen depreciation—the current-period USD/JPY rate was 159 yen versus 145 yen in the same period of the previous year—was also a contributing factor.

【Profit and Loss】Operating Income increased 94.9% year on year to ¥184.51B, while the Operating Income margin improved by 10.1pt to 28.8%, from 18.7% in the same period of the previous year. The SG&A expense ratio declined to 33.6%, from 38.9% in the previous year, a decrease of 5.4pt, with improved cost efficiency contributing to the increase in profit. In addition, other expenses declined substantially to ¥4.30B, from ¥21.33B in the previous year. This was a temporary factor resulting from the lapping of the ¥13.55B impairment loss recorded in the same period of the previous year, compared with ¥0.05B in the current period. Net finance income turned positive at ¥2.01B, compared with net finance expense of ¥4.23B in the previous year, resulting in Profit Before Tax of ¥186.51B (+106.3%). The effective tax rate was broadly unchanged at 24.0%, compared with 24.3% in the previous year, and Net Income attributable to owners of the parent increased +107.3%, broadly in line with Profit Before Tax. Both revenue and profits increased.

Segment Analysis

The Company operates as a single Pharmaceutical Business segment and therefore omits the presentation of segment information. Accordingly, product-level revenue composition is used as an alternative basis for analysis. XTANDI generated revenue of ¥276.6B, accounting for 43.2% of total revenue, and is the largest core product on a standalone basis. It grew steadily by +19% year on year, and the Company explained that progress was in line with expectations relative to its full-year forecast.

Meanwhile, growth was driven by the key strategic product portfolio: PADCEV (¥75.5B, +36%), IZERVAY (¥27.2B, +70%), VYLOY (¥21.1B, +51%), XOSPATA (¥21.6B, +27%), and VEOZAH (¥14.9B, +55%). The five products generated combined revenue of ¥160.3B, representing 25.0% of total revenue. These key strategic products together with XTANDI accounted for 68.2% of total revenue across six products and are estimated to have driven more than half of the ¥135.12B increase in revenue. Although operating income by product has not been disclosed, it is clear that the strong growth rates of growth products were a major driver of the Company-wide +94.9% increase in Operating Income.

Key Financial Metrics

Profitability: ROE was 7.3% on a quarterly annualized basis, while the Operating Income margin was 28.8%, compared with 18.7% in the same period of the previous year, an improvement of +10.1pt. The gross margin remained high at 80.9%, broadly unchanged from 80.9% in the previous year, or -0.4pt on a strict basis.
Cash flow quality: Operating Cash Flow (OCF)/Net Income was 0.61x, below 1.0x, indicating a delay in the conversion of profit into cash. Free Cash Flow was ¥17.23B (OCF + investing cash flow).
Investment efficiency: Investment in property, plant and equipment was ¥12.62B, compared with total depreciation and amortization of tangible and intangible assets of ¥49.89B, representing 0.25x and indicating a focus on maintaining and renewing existing assets. Including ¥45.53B of intangible asset acquisitions, total investment was ¥58.15B, demonstrating active investment in pipeline assets.
Financial soundness: The Equity Ratio was 52.6%, compared with 51.3% in the previous year, an improvement of +1.3pt. The current ratio was 120.3% (current assets of ¥1,485.60B / current liabilities of ¥1,234.76B).

Cash Flow Analysis

OCF was ¥86.48B (+57.7% year on year and 0.61x Net Income), indicating that cash generation did not increase to the same extent as Profit Before Tax.

Investing cash flow was -¥69.24B, primarily due to ¥12.62B of property, plant and equipment acquisitions, ¥45.53B of intangible asset acquisitions—including pipeline asset acquisitions such as ASP546C, VIR-5500, and ASP7317—and ¥12.25B of acquisitions of equity instruments.

Financing cash flow was -¥52.95B. Dividend payments of ¥69.87B were the largest use of cash, partially offset by a ¥29.87B increase in short-term borrowings. Share repurchases were small at ¥0.59B.

FCF was ¥17.23B (OCF + investing cash flow).

Cash generation assessment: Requires monitoring. A sharp increase in trade receivables (+¥84.89B, +11.4%) and higher corporate income tax payments (-¥62.39B, +86.7% year on year) weighed on OCF growth.

Earnings Quality

As the Company adopts IFRS, the concept of Ordinary Income is not used, and performance is evaluated on a Profit Before Tax basis. The difference between Profit Before Tax of ¥186.51B and Net Income of ¥141.75B consists of income taxes of ¥44.76B, corresponding to an effective tax rate of 24.0%; no unusual divergence unrelated to the tax burden was observed.

However, the improvement in Operating Income includes temporary factors. The lapping of the ¥13.55B impairment loss recorded in the same period of the previous year, compared with ¥0.05B in the current period, contributed to profit growth through the substantial decline in other expenses from ¥21.33B to ¥4.30B. Accordingly, structural improvements in earnings power and temporary factors are intermixed.

Comprehensive Income attributable to owners of the parent of ¥183.70B exceeded Net Income attributable to owners of the parent of ¥141.83B by ¥41.9B. This was primarily due to foreign currency translation adjustments for foreign operations of +¥41.61B, reflecting the effect of yen depreciation, rather than an improvement in underlying business earnings.

Earnings Forecast and Guidance

The Q1 progress rates against the full-year forecasts—Revenue of ¥2,220B, Operating Income of ¥395B, and Net Income of ¥300B—were 28.9% for Revenue, 46.7% for Operating Income, and 47.3% for Net Income attributable to owners of the parent. Compared with standard progress of 25% for Q1, Revenue was +3.9pt ahead, while profit was progressing more than +20pt ahead of schedule. Progress was therefore substantially front-loaded. The Company expects to increase investment in R&D from Q2 onward, and the plan to concentrate R&D expenses in the second half of the fiscal year is considered one reason why profit progress significantly exceeded revenue progress as of Q1. There were no revisions to the earnings forecast or dividend forecast for the current quarter.

Shareholder Returns

The full-year dividend forecast is ¥80 per share, implying a Payout Ratio of approximately 47.8% against full-year forecast EPS of ¥167.46. The current-quarter statement of cash flows records dividend payments of ¥69.87B, but these relate to the payment of the dividend for the previous fiscal year-end and were not covered by current-quarter FCF of ¥17.23B. Share repurchases were small at ¥0.59B, indicating a shareholder return policy centered on dividends.

Catalysts

【Short Term】An earnings briefing for securities analysts and institutional investors is scheduled for August 5, 2026. Increased penetration of PADCEV for the U.S. MIBC indication and progress in VYLOY’s Phase III LUCERNA trial—the target number of patient enrollments has already been achieved ahead of schedule—are expected to be reflected in future performance.

【Long Term】Key areas of focus include the start of enrollment in Phase III trials for setidegrasib and ASP2138, expansion of the Claudin18.2-targeted portfolio comprising VYLOY, ASP2138, and ASP546C, and progress under Sustainable Margin Transformation, which targets ¥200B in cost reductions during fiscal years 2026–2030.

Industry Benchmark (Reference, Compiled by the Company)

Industry Benchmark (pharma)

Profitability and Returns

Profitability was substantially above the industry median and positioned at a high level.

Growth and Capital Efficiency

Revenue growth also substantially exceeded the industry median, indicating a high growth rate within the industry.

Source: Compiled by the Company

Risk Factors

1. Increase in refund liabilities (U.S. rebates): Refund liabilities increased to ¥448.32B, from ¥422.56B at the end of the previous fiscal year, an increase of +6.1%. This suggests increasing pricing negotiation and chargeback pressure in the U.S. market and could potentially weigh on the gross margin.

2. Delay in cash conversion: OCF/Net Income was 0.61x, primarily due to an increase of ¥84.89B (+11.4%) in trade receivables. Cash generation has not kept pace with profit growth, making improvement from the next quarter onward a key monitoring point.

3. Increasing reliance on intangible assets and goodwill: Intangible assets reached ¥1,227.0B, or 27.7% of total assets, while goodwill reached ¥450.48B, or 23.2% of net assets. The Company also acquired ¥45.53B of intangible assets, including pipeline assets, during the quarter, requiring close monitoring of future impairment risk.

Key Takeaways from the Earnings Results

1. The Operating Income margin improved from 18.7% to 28.8%, an increase of 10.1pt, but this improvement includes the temporary effect of lapping the ¥13.55B impairment loss recorded in the same period of the previous year. Both structural cost efficiencies, reflected in the 5.4pt decline in the SG&A expense ratio, and temporary factors contributed; this should be considered when assessing earnings quality.

2. Full-year progress was 46–47% on a profit basis, substantially above the standard progress rate of 25%. As the Company has indicated a policy of increasing R&D investment in the second half, the earnings profile is structured such that profits are more likely to be front-loaded in the first half.

3. While OCF remained at 0.61x Net Income, trade receivables increased by double digits. Compared with the improvement in revenue and profit, cash generation has lagged somewhat, making future trends in cash conversion an area to monitor.

Theoretical Share Price (Reference Value)

This is a reference range mechanically calculated solely from publicly disclosed data using a residual income model (Ohlson-type model with an explicit 5-year fade period). It is not a forecast of the market share price or a recommendation to take any specific investment action.

Sensitivity: ¥1,311–¥1,388 for a ±1% change in the cost of equity, and ¥1,342–¥1,358 for a ±0.1 change in ω.

Notes:

• The EPS impact of approximately ¥4.9 per share resulting from a ±¥5 change in the assumed exchange rate is reflected in the bear/bull scenarios.
• Because Net Income progress against the full-year forecast was 47%, above the standard 25%, forecast EPS has been adjusted upward within a maximum range of +10% (as companies progressing ahead of schedule tend to exceed forecasts; the adjustment may be excessive for businesses with strong seasonality).
• Net assets as of the quarter-end are used, resulting in a timing difference relative to the full-year forecast.

(Calculation model: Residual Income Model / Interest rate reference month: 2026-07 / This value does not forecast or guarantee a future share price)

---

This report is an earnings analysis document automatically generated through AI-integrated analysis of XBRL earnings summary data and PDF earnings presentation materials. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly available earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting with professionals as necessary.

---End of Report---